Table.
Characterization of our novel anti-RBD antibodies on RBD-induced platelet activation.
| Clone name | IgG subtype | Inhibit RBD–ACE2 binding | Inhibit RBD-PLT binding | Inhibit P-selectin | Inhibit PAC-1 | Inhibit fibrinogen |
|---|---|---|---|---|---|---|
| 4F2 | IgG 1 | Strong | Yes | Yes (*) | Yes | Yes (*) |
| 4H10 | IgG 2a | Weak | Yes | Yes | Yes (*) | Yes (**) |
| 2B5 | IgG 2a | Weak | Yes | Yes | Yes (*) | Yes (*) |
| 4E10 | IgG 2b | Weak | Yes | Yes | Yes | Yes |
| 4H12 | IgG 1 | Strong | Yes | Yes | Yes (**) | Yes |
*P < 0.05, **P < 0.01, RBD + anti-RBD mAb vs. RBD + mIgG control.